BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 38235944)

  • 1. Rapid diurnal variation of serous retinal detachment during BRAF and MEK inhibitor treatment: A case series.
    Bravetti GE; Muggler K; Ben Aissa A; Thumann G; Malclès A
    Acta Ophthalmol; 2024 Jun; 102(4):e651-e656. PubMed ID: 38235944
    [No Abstract]   [Full Text] [Related]  

  • 2. MEK inhibitor-associated retinopathy (MEKAR) in metastatic melanoma: Long-term ophthalmic effects.
    Urner-Bloch U; Urner M; Jaberg-Bentele N; Frauchiger AL; Dummer R; Goldinger SM
    Eur J Cancer; 2016 Sep; 65():130-8. PubMed ID: 27497344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intracranial antitumor activity with encorafenib plus binimetinib in patients with melanoma brain metastases: A case series.
    Holbrook K; Lutzky J; Davies MA; Davis JM; Glitza IC; Amaria RN; Diab A; Patel SP; Amin A; Tawbi H
    Cancer; 2020 Feb; 126(3):523-530. PubMed ID: 31658370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management.
    Gogas HJ; Flaherty KT; Dummer R; Ascierto PA; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Sileni VC; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Gollerkeri A; Pickard MD; Robert C
    Eur J Cancer; 2019 Sep; 119():97-106. PubMed ID: 31437754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transient MEK inhibitor-associated retinopathy in metastatic melanoma.
    Urner-Bloch U; Urner M; Stieger P; Galliker N; Winterton N; Zubel A; Moutouh-de Parseval L; Dummer R; Goldinger SM
    Ann Oncol; 2014 Jul; 25(7):1437-1441. PubMed ID: 24864047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Encorafenib and binimetinib for the treatment of BRAF V600E/K-mutated melanoma.
    Rose AAN
    Drugs Today (Barc); 2019 Apr; 55(4):247-264. PubMed ID: 31050693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.
    Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion-Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT
    Lancet Oncol; 2018 May; 19(5):603-615. PubMed ID: 29573941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FREQUENT SUBCLINICAL MACULAR CHANGES IN COMBINED BRAF/MEK INHIBITION WITH HIGH-DOSE HYDROXYCHLOROQUINE AS TREATMENT FOR ADVANCED METASTATIC BRAF MUTANT MELANOMA: Preliminary Results From a Phase I/II Clinical Treatment Trial.
    Nti AA; Serrano LW; Sandhu HS; Uyhazi KE; Edelstein ID; Zhou EJ; Bowman S; Song D; Gangadhar TC; Schuchter LM; Mitnick S; Huang A; Nichols CW; Amaravadi RK; Kim BJ; Aleman TS
    Retina; 2019 Mar; 39(3):502-513. PubMed ID: 29324592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Phase Ib/II Study of the BRAF Inhibitor Encorafenib Plus the MEK Inhibitor Binimetinib in Patients with
    Sullivan RJ; Weber J; Patel S; Dummer R; Carlino MS; Tan DSW; Lebbé C; Siena S; Elez E; Wollenberg L; Pickard MD; Sandor V; Ascierto PA
    Clin Cancer Res; 2020 Oct; 26(19):5102-5112. PubMed ID: 32669376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical experience with combination BRAF/MEK inhibitors for melanoma with brain metastases: a real-life multicenter study.
    Drago JZ; Lawrence D; Livingstone E; Zimmer L; Chen T; Giobbie-Hurder A; Amann VC; Mangana J; Siano M; Zippelius A; Dummer R; Goldinger SM; Sullivan RJ
    Melanoma Res; 2019 Feb; 29(1):65-69. PubMed ID: 30376465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An overview of binimetinib for the treatment of melanoma.
    Specenier P
    Expert Opin Pharmacother; 2020 May; 21(7):747-754. PubMed ID: 32100585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Severe pyrexia from nivolumab-resistant advanced melanoma after successful combined therapy with encorafenib plus binimetinib.
    Amagai R; Fujimura T; Kambayashi Y; Sato Y; Tanita K; Ohuchi K; Hashimoto A; Aiba S
    J Dermatol; 2020 Jun; 47(6):654-657. PubMed ID: 32293049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Protein kinase inhibitors can induce retinopathy].
    Lindboe JB; Ahmed HJ; Christakopoulos CE
    Ugeskr Laeger; 2020 Aug; 182(32):. PubMed ID: 32800052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Left ventricular ejection fraction decrease related to BRAF and/or MEK inhibitors in metastatic melanoma patients: A retrospective analysis.
    Berger M; Amini-Adlé M; Maucort-Boulch D; Robinson P; Thomas L; Dalle S; Courand PY
    Cancer Med; 2020 Apr; 9(8):2611-2620. PubMed ID: 32056395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.
    Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT
    Lancet Oncol; 2018 Oct; 19(10):1315-1327. PubMed ID: 30219628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Erythema multiforme-like rash upon anti-melanoma therapy with BRAF and MEK inhibitors.
    Grän F; Goebeler M; Gesierich A
    Eur J Dermatol; 2019 Feb; 29(1):107-108. PubMed ID: 30998207
    [No Abstract]   [Full Text] [Related]  

  • 17. Update on BRAF and MEK inhibition for treatment of melanoma in metastatic, unresectable, and adjuvant settings.
    Broman KK; Dossett LA; Sun J; Eroglu Z; Zager JS
    Expert Opin Drug Saf; 2019 May; 18(5):381-392. PubMed ID: 30977681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAF
    Schreuer M; Jansen Y; Planken S; Chevolet I; Seremet T; Kruse V; Neyns B
    Lancet Oncol; 2017 Apr; 18(4):464-472. PubMed ID: 28268064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inflammatory side effects of BRAF and MEK inhibitors.
    Mackin AG; Pecen PE; Dinsmore AL; Patnaik JL; Gonzalez R; Robinson WA; Palestine AG
    Melanoma Res; 2019 Oct; 29(5):522-526. PubMed ID: 30870269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Empiric Therapy with BRAF and MEK Inhibitors in Metastatic Melanoma.
    Cann CG; Tillman BF; Davis EJ; Johnson DB
    Oncologist; 2019 Nov; 24(11):1495-1496. PubMed ID: 31213499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.